https://jbda.sciforce.org/JBDA <p>Bridging Innovation and Healthcare: Journal of BioEngineering and Drug Administration (JBDA) by Sciforce Publications</p> <p>Step into the world of cutting-edge bioengineering and drug administration with the Journal of BioEngineering and Drug Administration (JBDA), a leading publication by Sciforce Publications. JBDA serves as a gateway to the latest research and advancements in the fields of bioengineering, drug development, and regulatory affairs. In this web content, we will explore the significance of JBDA, its contributions to the scientific community, and the dynamic realm of bioengineering and drug administration.</p> <p> </p> www.sciforce.org en-US Journal of BioEngineering and Drug Administration https://jbda.sciforce.org/JBDA/article/view/25 <p>Cancer therapeutics are designed to interfere with one or more events in cell propagation or survival. However, the healthy cells may also need to thrive and avoid apoptosis, anticancer agents can be toxic to such cells. To minimize these toxicities, approaches have been developed wherein the therapeutic agent is targeted to tumor cells through conjugation to a tumor-cell-specific small-molecule ligand, thus reducing delivery to normal cells and the associated collateral toxicity. This article describes the novel tris(nonofluoro <em>tert</em>-butyl)-DOTA derived drug imaging agents in the design of ligand-targeted drugs and ligand–drug conjugates and ligand–imaging-agent conjugates.</p> Suryakiran Navath Copyright (c) 2021 Journal of BioEngineering and Drug Administration 2021-02-26 2021-02-26 1 1 1 14